Previous close | 90.02 |
Open | 90.60 |
Bid | 88.30 x N/A |
Ask | 92.82 x N/A |
Day's range | 90.19 - 90.73 |
52-week range | 73.33 - 93.86 |
Volume | |
Avg. volume | 1,993,180 |
Market cap | 191.952B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 30.70 |
EPS (TTM) | 2.95 |
Earnings date | N/A |
Forward dividend & yield | 3.20 (3.55%) |
Ex-dividend date | 09 Mar 2023 |
1y target est | N/A |
Novartis generic arm, Sandoz, which will be spun off, expects strong growth as a standalone company, driven by increasing contribution from biosimilars.
The FDA grants priority review to Vertex (VRTX)/CRISPR's (CRSP) filings for exa-cel in SCD, with a final decision expected in December.
FDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy for the treatment of patients with first-line advanced or metastatic biliary tract cancer.
Toll Brothers, Walmart, W.W. Grainger, Novartis and Graphic Packaging Holding are part of the Zacks Screen of the Week article.
Toll Brothers (TOL), Walmart (WMT), W.W. Grainger (GWW), Novartis (NVS) and Graphic Packaging (GPK) could be compelling picks for outperformance amid market volatility.
(Reuters) -European shares were subdued on Thursday as rate-sensitive technology shares and consumer staples slipped on expectations of further interest rate hikes by major central banks, while a sharp slide in Vodafone shares weighed on the telecoms sector. The pan-European STOXX 600 index was flat, with the rate-sensitive technology sector down 0.3%. Britain's FTSE 100 led losses among regional peers, with export-heavy consumer staples such as Unilever and Reckitt Benckiser Group PLC under pressure as the pound rallied near 0.9% on expectations of more interest rate hikes by the Bank of England after a forecast showed UK inflation is set to remain elevated this year.
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to further extending global leadership in attractive and growing generics and biosimilars market, via purpose-driven strategy with focus on access and sustainability Six strategic levers to drive long-term investor value; attractive financial outlook, including targeted investment grade credit profile and progress
European stock markets edged lower Thursday, with investors searching for direction ahead of the release of eurozone growth data as well as next week’s key central bank meetings. European stocks appear to be something of a holding pattern ahead of the next week’s policy-setting meetings from both the European Central Bank and the U.S. Federal Reserve. The ECB is widely expected to raise interest rates by a further 25 basis points on Thursday week, with President Christine Lagarde saying earlier this week that inflation pressures remain powerful and borrowing costs will be raised further to tackle them.
Novartis (NYSE: NVS) is a company in transition. Now, Novartis is close to completing this long-winded transition with the upcoming spin-off of its generic drug business, Sandoz, later this year. With a debt-to-equity ratio of 47%, Novartis' balance sheet isn't overly levered, especially compared to many of its big pharma peers.
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
Merck (MRK) files a lawsuit against claiming that the federal government is violating the Constitution by forcing drugmakers to negotiate prices at below market rates.
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.
Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's
Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
After losing some value lately, a hammer chart pattern has been formed for Novartis (NVS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall survival*1 The safety profile of Kisqali was favorable at 400 mg with low rates of symptomatic adv
Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.